KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovoCure (NVCR) Depreciation & Amortization (CF) (2016 - 2025)

NovoCure's Depreciation & Amortization (CF) history spans 12 years, with the latest figure at $4.2 million for Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) rose 35.89% year-over-year to $4.2 million; the TTM value through Dec 2025 reached $14.6 million, up 30.4%, while the annual FY2025 figure was $14.6 million, 30.4% up from the prior year.
  • Depreciation & Amortization (CF) for Q4 2025 was $4.2 million at NovoCure, up from $3.7 million in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $4.2 million in Q4 2025 and bottomed at $2.4 million in Q1 2021.
  • The 5-year median for Depreciation & Amortization (CF) is $2.7 million (2023), against an average of $2.9 million.
  • The largest annual shift saw Depreciation & Amortization (CF) fell 12.31% in 2024 before it skyrocketed 49.02% in 2025.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $2.7 million in 2021, then grew by 1.24% to $2.7 million in 2022, then increased by 0.85% to $2.7 million in 2023, then rose by 13.99% to $3.1 million in 2024, then surged by 35.89% to $4.2 million in 2025.
  • Per Business Quant, the three most recent readings for NVCR's Depreciation & Amortization (CF) are $4.2 million (Q4 2025), $3.7 million (Q3 2025), and $3.4 million (Q2 2025).